Bob G Schultz (B G Schultz)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 15

Top Topics

Health Promotion

Extracorporeal Membrane Oxygenation

Genetic Diversity

Top Venues

Expert review of pharmacoeconomics & outcomes research

Journal of medical economics

Expert review of hematology

BMC gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Mark Oppe, Bogdan Muresan, Katie Chan, Xenia Radu, Bob G Schultz, Robin S Turpin, Arnaud Nucit, Elisabetta Fenu
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Mark Oppe, Bogdan Muresan, Katie Chan, Xenia Radu, Bob G Schultz, Robin S Turpin, Arnaud Nucit, Elisabetta Fenu
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Miguel A Escobar, Neha Agrawal, Sagnik Chatterjee, Swastik Bhattacharya, Jorge Caicedo, Michael Bullano, Bob G Schultz
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. Journal of medical economics (2023)
Miguel A Escobar, Michael Bullano, Ali G Mokdad, Jorge Caicedo, Bob G Schultz, Qi Fan, Sumit Verma
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert review of hematology (2023)
Nathan T Connell, Jorge Caicedo, N Nieto, Sagnik Chatterjee, A Hait, A K Gupta, Michael Bullano, Bob G Schultz
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. Expert review of pharmacoeconomics & outcomes research (2023)
Mark Oppe, Bogdan Muresan, Katie Chan, Xenia Radu, Bob G Schultz, Robin S Turpin, Arnaud Nucit, Elisabetta Fenu
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. Expert review of pharmacoeconomics & outcomes research (2023)
Chintal H Shah, Princic Nicole, Kristin A Evans, Bob G Schultz
Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab. Journal of medical economics (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Vipul Jairath, Russell D Cohen, Edward V Loftus, Ninfa Candela, Karen Lasch, Bob G Schultz
Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis. BMC gastroenterology 22 (1) (2022)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research (2022)
Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Michael Bullano
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Current medical research and opinion 38 (10) (2022)
Mark Oppe, Bogdan Muresan, Katie Chan, Xenia Radu, Bob G Schultz, Robin S Turpin, Arnaud Nucit, Elisabetta Fenu
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. Expert review of pharmacoeconomics & outcomes research (2022)